Pfizer’s flibanserin, marketed as Addyi, underwent rigorous clinical trials. Phase 3 trials involved over 1,700 premenopausal women experiencing hypoactive sexual desire disorder (HSDD).
Results showed a statistically significant increase in satisfying sexual events per month in women treated with flibanserin compared to the placebo group. However, the magnitude of this increase was modest.
The FDA’s approval acknowledges the efficacy, but also highlights side effects such as nausea, dizziness, and somnolence. These side effects necessitate careful consideration and monitoring during treatment.
Individual responses vary greatly. Some women experienced significant improvements, while others saw minimal change. Open communication with your doctor is paramount to assess suitability and manage potential side effects.
Researchers continue to investigate the long-term effects and explore alternative treatment options for HSDD. Current research focuses on refining treatment protocols and identifying potential biomarkers predicting individual response to flibanserin.
Before beginning treatment, discuss your medical history, current medications, and other health concerns with your healthcare provider. They can help determine if flibanserin is appropriate for you and monitor your progress.
